{
  "abstract": "Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is thought to affect 25% of adults in the United Kingdom. It represents the hepatic manifestation of the metabolic syndrome. It is difficult to predict which patients will develop cirrhosis and its associated complications, and which patients will pursue a course of simple steatosis. There are promising developments for drug therapy in the field of metabolic dysfunction-associated steatohepatitis (MASH). It is therefore important that patients are risk-stratified in a timely manner.Method From 1st April 2023- 9th May 2025, 528 new referrals of patients with suspected MASLD were received by the Regional Liver Unit, Belfast from primary and secondary care. Patients with indeterminate or raised FIB-4 scores with no features of concern (such as synthetic dysfunction or abnormalities in a non-invasive liver screen) were allocated to an appointment at the new nurse-led MASLD clinic.This clinic was set up as a ‘one-stop shop’. This allows risk assessment including BMI and blood pressure measurement, a Fibroscan, and completion liver screen. Interrogation of metabolic syndrome risk factors and alcohol screening takes place, with appropriate patient education. Patients are provided with information resources from the British Liver Trust.A decision is made on the day as to whether the patient can be safely discharged to the community with repeat FIB-4 score in 2–3 years (if liver stiffness measurement – LSM<8kPa), or whether they need ongoing review in the liver service. Patients with LSM>12kPa are allocated to an urgent consultant review and enrolled in hepatocellular carcinoma (HCC) surveillance if appropriate.Results Of 528 new patient referrals, 277 (52%) referrals were discharged back to primary care following assessment. 94 (18%) patients were offered a routine clinic with a follow up Fibroscan in 2 years based on LSM 8–11kPa. 121 (23%) had scans supportive of advanced fibrosis/cirrhosis with urgent referral to a consultant clinic and enrolment in HCC surveillance. 5% of patients (27) did not attend their scheduled appointment.Abstract P12 Figure 1Conclusion The nurse-led clinic has already risk-stratified and educated 501 patients with MASLD, facilitating timely discharge from secondary care for over 50% of patients whilst ensuring individualized follow-up of higher risk patients. 277 new consultant clinic appointments have been saved, amounting to an approximate total saving of £45,500 based on Department of Health OP Costings 2022–2023. This, in turn, has aided in the reduction of consultant clinic waiting times, and has allowed timely assessment of patients in the nurse-led clinic.",
  "authors": [
    {
      "affiliations": [
        "Royal Victoria Hospital, Belfast, UK"
      ],
      "name": "Jessica Brown"
    },
    {
      "affiliations": [
        "Royal Victoria Hospital, Belfast, UK"
      ],
      "name": "Rogan Canning"
    },
    {
      "affiliations": [
        "Royal Victoria Hospital, Belfast, UK"
      ],
      "name": "Hannah R McDowell"
    },
    {
      "affiliations": [
        "Royal Victoria Hospital, Belfast, UK"
      ],
      "name": "Neil McDougall"
    },
    {
      "affiliations": [
        "Royal Victoria Hospital, Belfast, UK"
      ],
      "name": "Leanne Stratton"
    }
  ],
  "title": "P12 A nurse-led, one-stop-shop approach to MASLD assessment, risk stratification and patient education: the belfast experience",
  "uid": "38aa863e-415f-51dc-a4b0-e3e452f224cf"
}